Biphenyl

Biphenyl

SCHEMBL3384157

O=C(O)c1ccccn1.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.87

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.87
▸ L3MBTL1 Q9Y468 2/20 0.87
▸ NAPRT Q6XQN6 1/20 0.87
▸ P4HTM Q9NXG6 1/20 0.87
▸ CES2 O00748 1/20 0.61
▸ CES1 P23141 1/20 0.61
▸ KMT2A Q03164 2/20 0.59
▸ ALDH1A1 P00352 2/20 0.57
▸ HDAC1 Q13547 1/20 0.53
▸ GSK3B P49841 1/20 0.52
▸ KDM4E B2RXH2 2/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ MAPT P10636 1/20 0.50
▸ PKM P14618 1/20 0.50
▸ TLR7 Q9NYK1 1/20 0.49
▸ KMO O15229 2/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ ACMSD Q8TDX5 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Picolinic Acid SCHEMBL28737810 0.93 LMNA (1.00) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL7457912 0.93 LMNA (1.00) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL29368665 0.93 — —
2-Picolinic Acid SCHEMBL674837 0.93 LMNA (1.00) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL36055 0.93 — —
2-Picolinic Acid SCHEMBL3843691 0.91 LMNA (0.95) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL673571 0.91 LMNA (0.95) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL2168036 0.91 LMNA (0.95) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL22835776 0.91 LMNA (0.95) LMNAL3MBTL1NAPRTP4HTMCES2
2-Picolinic Acid SCHEMBL20721125 0.91 LMNA (0.95) LMNAL3MBTL1NAPRTP4HTMCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1832945-A Diphenylpyridine derivatives, their preparation and their therapeutic use SANOFI AVENTIS (FR) 2006-09-13 — — CN claimed
WO-2020034939-A1 CHEMILUMINESCENCE ANALYSIS METHOD AND APPLICATION THEREOF 博阳生物科技(上海)有限公司 2020-02-20 — — WO disclosed
EP-1932832-B1 TRIARYLCARBOXYLIC ACID DERIVATIVE ASTELLAS PHARMA INC (JP) 2010-12-01 — — EP disclosed
US-7816558-B2 Triarylcarboxylic acid derivative ASTELLAS PHARMA INC. (JP) 2010-10-19 — — US disclosed
US-20090018104-A1 Triarylcarboxylic Acid Derivative ASTELLAS PHARMA INC. (JP) 2009-01-15 — — US disclosed
EP-1932832-A1 TRIARYLCARBOXYLIC ACID DERIVATIVE Astellas Pharma Inc. (JP) 2008-06-18 — — EP disclosed
CN-1832945-A Diphenylpyridine derivatives, their preparation and their therapeutic use SANOFI AVENTIS (FR) 2006-09-13 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018104-A1 Triarylcarboxylic Acid Derivative XDH, NLRP3, UACA LMNA 3251/4885L3MBTL1 2760/4885NAPRT 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback